Final 20-week JADE data show OLN324 delivers improved durability, retinal drying, and vision gains versus Vabysmo in DME and wAMD, supporting Phase 3 development.
Written By: A. Mohamed Musharaf, BPharm
Reviewed By: Pharmacally Editorial Team
Innovent Biologics and partner Ollin Biosciences reported final 20-week data from the Phase 1b JADE study, showing that OLN324 (IBI324) delivered differentiated efficacy and durability versus Vabysmo in patients with diabetic macular edema (DME) and wet age-related macular degeneration (wAMD).
This update builds on Week 12 results that showed superior retinal drying in DME and comparable outcomes in wAMD, with the latest data reinforcing sustained efficacy and reduced treatment burden.
Strong Durability and Reduced Retreatment Rates
The JADE trial enrolled 164 U.S. patients who received three initial monthly doses followed by a 12-week off-treatment period. At Week 20, OLN324 4 mg showed greater retinal drying in DME and sustained vision gains that numerically exceeded faricimab.
Notably, 93% of OLN324 patients required no retreatment (vs. 89% for faricimab); in wAMD, rates were similar at 82% vs. 81%.
Vision Gains and Anatomic Improvements
In wAMD, both agents achieved rapid retinal drying by Week 12, but OLN324 4 mg maintained a +2.2-letter visual acuity advantage through Week 20.
It also demonstrated faster and approximately 50% greater reductions in pigment epithelial detachment (PED) thickness at Week 12, with more durable effects through Week 20.
Favorable Safety Profile
OLN324 maintained a clean profile, with no intraocular inflammation (vs. one case with faricimab) and no retinal vasculitis or occlusive events.
Mechanism and Differentiation
As a next-generation VEGF/Ang2 bispecific antibody, OLN324 is designed with higher Ang2 potency, increased molar dosing, and a smaller molecular format, aiming to improve vascular stability and reduce leakage, inflammation, and fibrosis.
Commenting on the data, Ollin CEO Jason Ehrlich, M.D., Ph.D., said OLN324’s efficacy, durability, and safety profile position it as a potential first-line therapy in diseases where treatment burden remains a key challenge.
Next Steps: Global Phase 3 Trials
These results support advancing OLN324 into Phase 3 trials in DME and wAMD, with planned enrollment across North America, Europe, Japan, China, and South Korea, subject to regulatory discussions.
Full details from the JADE study are expected to be presented at upcoming medical and scientific conferences, as development progresses toward late-stage evaluation.
References
Innovent’s Partner Ollin Biosciences Announces Final Data from Randomized Head-to-Head Study of IBI324 Compared to Faricimab (Vabysmo) in Wet Age-Related Macular Degeneration and Diabetic Macular Edema, 31 March 2026, Press Release
About the Writer
Mohamed Musharaf A is a Pharmacy graduate from Ariyur, Puducherry, with a strong interest in data analysis and its application in healthcare. He is particularly interested in using data-driven insights to support pharmacovigilance and medical writing, with a focus on understanding complex datasets and translating them into meaningful, actionable solutions. Known for his dedication to learning and attention to detail, he continuously works to strengthen his analytical and domain knowledge.